Ibutamoren Mesylate Increases Body Weight Gain, Serum IGF-1 and GH levels

Description

Ibramolen mesylate is a drug that acts as a potent, orally potent, growth-stimulating hormone secretion, mimicking the action of gh to stimulate endogenous hormones.

Function

Ibramolen mesylate has been shown to increase the release and production of persistently increased plasma levels of some hormones including gh and insulin-like growth factor 1 (igf-1), but does not affect cortisol levels. Potential treatments currently under development reduce levels of these hormones, such as in children or the elderly with growth hormone deficiency, and human studies have shown increased muscle and bone mineral density, making it a promising treatment for frail older adults. It also alters the metabolism of body fat, so it may have applications in the treatment of obesity.

In vivo studies

Ibutamoren mesylate (5 mg/kg/day) results in a statistically significant increases body weight gain and increases serum IGF-1 and GH levels in dogs. Ibutamoren mesylate results in no significant increase in CSF IGF-1 or GH levels on days 7 or 15 of the study. Pretreating mice with GH blocks activation of these neurons by Ibutamoren mesylate (50 μg, i.p.). In the knockout mice, both GH and octreotide fail to inhibit Ibutamoren mesylate activation of arcuate neurons. Chronic oral administration of MK-0677 is associated with significant increases in GH and IGF-I levels that are maintained for the duration of the treatment. The GH profile following MK-0677 administration consists of episodic increases above control. MK-0677 significantly increases peak GH concentrations after oral administration. MK-0677 is a potent GH secretagogue that induces an immediate, large, long lasting increase in GH levels when administered orally or i.v.